Trial reportJournal of gastroenterology2008
Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.
Trial report in Journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Nutritional support for liver disease.The Cochrane database of systematic reviews · 2012Pooled it
- Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment.Journal of gastroenterology · 2015Trial
- Impact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma.Cancers · 2025Article
- Serum Branched-Chain Amino Acids and Long-Term Complications of Liver Cirrhosis: Evidence from a Population-Based Prospective Study.Nutrients · 2024Article
- Review
- Use of Branched-Chain Amino Acids as a Potential Treatment for Improving Nutrition-Related Outcomes in Advanced Chronic Liver Disease.Nutrients · 2023Review
- Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis.International journal of molecular sciences · 2022Article
- Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis.World journal of clinical cases · 2022Article
- A Comprehensive Review Evaluating the Impact of Protein Source (Vegetarian vs. Meat Based) in Hepatic Encephalopathy.Nutrients · 2021Review
- Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.World journal of hepatology · 2019Review
- Observational
- Evidence-based clinical practice guidelines for liver cirrhosis 2015.Journal of gastroenterology · 2016Review
- Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond.Advances in nutrition (Bethesda, Md.) · 2016Review
- Perioperative nutritional support and fluid therapy in patients with liver diseases.Hepatobiliary surgery and nutrition · 2014Review
- Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.World journal of gastroenterology · 2014Review
- Branched-chain amino acids in liver diseases.World journal of gastroenterology · 2013Review
- The complex role of branched chain amino acids in diabetes and cancer.Metabolites · 2013Article
- Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis.Hepatology research : the official journal of the Japan Society of Hepatology · 2013Article
- Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis.Gastroenterology research and practice · 2013Article
- Early administration of branched-chain amino acid granules.World journal of gastroenterology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branched-chain amino acid (BCAA) granules for oral use (TK-98) on disease progression.
methodsPatients who had compensated liver cirrhosis due to hepatitis C virus with baseline serum albumin levels between 3.6 and 4.5 g/dl were assigned to the TK-98 group, which was treated with BCAA granules (TK-98) for 168 weeks, or to a control group (no treatment).
resultsNo symptoms indicating decompensated cirrhosis, including ascites, edema, and hepatic encephalopathy were reported in either the TK-98 or control group during the study observation period. Hepatocellular carcinoma (HCC) was noted in eight of the 39 patients studied, and of these three received TK-98 (15.8%) and five were untreated (25.0%). A time-to-event analysis for the effect of BCAA therapy on development of HCC revealed no statistically significant differences between the two groups. However, an additional analysis of data from a subgroup with a baseline serum albumin level of <4.0 g/dl showed that the incidence of HCC was likely to be lower in BCAA-treated patients.
conclusionsBCAA may inhibit hepatic carcinogenesis in patients with compensated cirrhosis with a serum albumin level of <4.0 g/dl.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.